Aliases & Classifications for Cannabis Abuse

Summaries for Cannabis Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cannabis despite negative consequences.

MalaCards based summary : Cannabis Abuse, also known as marijuana abuse, is related to cocaine dependence and cannabis dependence. An important gene associated with Cannabis Abuse is CNR1 (Cannabinoid Receptor 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Ras signaling pathway. The drugs Dopamine and Clozapine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and lung, and related phenotype is no phenotypic analysis.

Related Diseases for Cannabis Abuse

Graphical network of the top 20 diseases related to Cannabis Abuse:



Diseases related to Cannabis Abuse

Symptoms & Phenotypes for Cannabis Abuse

MGI Mouse Phenotypes related to Cannabis Abuse:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 8.92 BDNF CHRNA3 CNR1 NGF

Drugs & Therapeutics for Cannabis Abuse

Drugs for Cannabis Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Clozapine Approved Phase 4 5786-21-0 2818
3
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
4 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
5
Serotonin Phase 4,Phase 2 50-67-9 5202
6 Adrenergic Agents Phase 4,Phase 2,Phase 3
7 Serotonin Agents Phase 4,Phase 2
8 Serotonin Antagonists Phase 4
9 GABA Agents Phase 4
10 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
11 Tranquilizing Agents Phase 4,Phase 3
12 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
13 Dopamine Agents Phase 4
14 Dopamine Antagonists Phase 4
15 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Atomoxetine Hydrochloride Phase 4,Phase 2
17 Antipsychotic Agents Phase 4,Phase 3
18
Ethanol Approved Phase 2, Phase 3, Phase 1 64-17-5 702
19
Dronabinol Approved, Illicit Phase 2, Phase 3,Phase 1,Early Phase 1 1972-08-3 16078 2978
20
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
21 Anti-Infective Agents Phase 2, Phase 3,Phase 1
22 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 1
23 Analgesics Phase 2, Phase 3,Phase 1,Early Phase 1
24 Hallucinogens Phase 2, Phase 3,Early Phase 1
25 Analgesics, Non-Narcotic Phase 2, Phase 3,Phase 1,Early Phase 1
26 Hormone Antagonists Phase 2, Phase 3,Early Phase 1
27 Hormones Phase 2, Phase 3,Early Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Early Phase 1
29 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 1,Early Phase 1
30 Autonomic Agents Phase 2, Phase 3,Phase 1
31 Cannabinoid Receptor Agonists Phase 2, Phase 3,Early Phase 1
32 Adrenergic Agonists Phase 2, Phase 3
33 Adrenergic alpha-2 Receptor Agonists Phase 2, Phase 3
34 Adrenergic alpha-Agonists Phase 2, Phase 3
35 Sympatholytics Phase 2, Phase 3
36 Antihypertensive Agents Phase 2, Phase 3
37 Quetiapine Fumarate Phase 3 111974-72-2
38
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
39
Topiramate Approved Phase 2 97240-79-4 5284627
40
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
41 Respiratory System Agents Phase 2
42 N-monoacetylcystine Phase 2
43 Antidotes Phase 2
44 Expectorants Phase 2
45 Protective Agents Phase 2
46 Antioxidants Phase 2
47 Antiviral Agents Phase 2
48 Serotonin Uptake Inhibitors Phase 2
49 Neuroprotective Agents Phase 2
50 Cytochrome P-450 CYP2D6 Inhibitors Phase 2

Interventional clinical trials:

(show all 31)

# Name Status NCT ID Phase Drugs
1 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
2 Clozapine for Cannabis Use in Schizophrenia Active, not recruiting NCT01639872 Phase 4 Clozapine;Risperidone
3 Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE Terminated NCT00687609 Phase 4 Atomoxetine
4 A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers Unknown status NCT00484367 Phase 2, Phase 3
5 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Recruiting NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
6 Quetiapine XR in Schizophrenic Patients Terminated NCT01071135 Phase 3 Quetiapine XR
7 Integration of (iSBIRT) for Teen Drug Use Into a Pediatric Network Withdrawn NCT01454206 Phase 2, Phase 3
8 Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal Unknown status NCT01439828 Phase 2 N-acetylcystein
9 Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents Completed NCT01110434 Phase 2 Topiramate;Placebo
10 The Teen Marijuana Check-Up Completed NCT00350285 Phase 2
11 Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence Completed NCT00149643 Phase 2 Fluoxetine
12 Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder Completed NCT00142961 Phase 2 Atomoxetine
13 Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders Completed NCT01875796 Phase 1
14 Relapse Prevention for Suicidal Dually Diagnosed Youths Completed NCT00589641 Phase 1
15 Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment Completed NCT00783185 Phase 1
16 Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation Completed NCT01037608 Phase 1 Sativex(Registered Trademark);THC
17 Medications Development for the Treatment of Cannabis Related Disorders Completed NCT01204723 Phase 1 Placebo Aprepitant;Active Aprepitant
18 Trial of Computerized SBI to Reduce Teen Alcohol Use Withdrawn NCT01784627 Phase 1
19 INCA - Intervention and Neuropsychology in Cannabis Abuse Unknown status NCT00279604
20 Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis Completed NCT00484302
21 Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse Completed NCT00798109
22 Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms Completed NCT01603992
23 Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia Completed NCT00376233
24 Study Comparing Two Types of Psychotherapy for Treating Depression and Substance Abuse Completed NCT00108407
25 First Episode Schizophrenia and Cannabis-Related Disorder Study Completed NCT00573287 clozapine;risperidone
26 Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer Completed NCT01647425
27 Dronabinol Interactions With Cognitive Enhancing Drug in Humans Completed NCT00842985 Early Phase 1 drug condition
28 COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE Recruiting NCT02319746
29 Treatment for Teens With Alcohol Abuse and Depression Recruiting NCT02227589
30 Affective Management Training for Cannabis Misuse Recruiting NCT03432013
31 Electrophysiological Study of the Functioning of Magnocellular Visual Pathway in Regular Cannabis Users Recruiting NCT02864680

Search NIH Clinical Center for Cannabis Abuse

Genetic Tests for Cannabis Abuse

Anatomical Context for Cannabis Abuse

MalaCards organs/tissues related to Cannabis Abuse:

38
Testes, Brain, Lung, Thyroid

Publications for Cannabis Abuse

Articles related to Cannabis Abuse:

(show top 50) (show all 101)
# Title Authors Year
1
The Cannabis Abuse Screening Test and the DSM-5 in the general population: Optimal thresholds and underlying common structure using multiple factor analysis. ( 29124816 )
2017
2
Long lasting effects of chronic heavy cannabis abuse. ( 28314070 )
2017
3
The Cannabis Abuse Screening Test (CAST) revisited: examining measurement invariance by age. ( 27723274 )
2016
4
Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients. ( 26935430 )
2016
5
Transverse myelitis associated with heroin and cannabis abuse: a new issue from the past. ( 27003705 )
2016
6
Shifting the Paradigm: Adolescent Cannabis Abuse and the Need for Early Intervention. ( 26800275 )
2016
7
Assessing the structure of the CAST (Cannabis Abuse Screening Test) in 13 European countries using multigroup analyses. ( 27981662 )
2016
8
Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia. ( 25716487 )
2015
9
Methamphetamine and cannabis abuse in adolescence: a quasi-experimental study on specific and long-term neurocognitive effects. ( 25636791 )
2015
10
The influence of age and gender on the likelihood of endorsing cannabis abuse/dependence criteria. ( 25481449 )
2015
11
Concomitant cannabis abuse/dependence in patients treated with opioids for non-cancer pain. ( 26246069 )
2015
12
Sex-dependent vulnerability to cannabis abuse in adolescence. ( 25941498 )
2015
13
Properties of the Cannabis Abuse Screening Test (CAST) in the general population. ( 26077195 )
2015
14
Commentary on Kosty et al. (2015): Cannabis abuse from one generation to the next-a heightened vulnerability in women? ( 26094497 )
2015
15
Authors' Response to "Parental Cannabis Abuse and Accidental Intoxication in Children: Prevention by Detecting Neglectful Situations and At-Risk Families". ( 26427950 )
2015
16
Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. ( 24682777 )
2014
17
Cannabis abuse and age at onset in schizophrenia patients with large, rare copy number variants. ( 24685822 )
2014
18
Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. ( 24788457 )
2014
19
Cannabinoid hyperemesis should be recognised as an effect of chronic cannabis abuse. ( 25120899 )
2014
20
Predicting cannabis abuse screening test (CAST) scores: a recursive partitioning analysis using survey data from Czech Republic, Italy, the Netherlands and Sweden. ( 25264894 )
2014
21
Functioning of Cannabis Abuse and Dependence Criteria Across Two Different Countries: The United States and The Netherlands. ( 25363693 )
2014
22
Long-term cannabis abuse and early-onset cannabis use increase the severity of cocaine withdrawal during detoxification and rehospitalization rates due to cocaine dependence. ( 25262527 )
2014
23
The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. ( 24990397 )
2014
24
Parental Cannabis Abuse and Accidental Intoxications in Children: Prevention by Detecting Neglectful Situations and At-Risk Families. ( 25407034 )
2014
25
Additive effects of childhood abuse and cannabis abuse on clinical expressions of bipolar disorders. ( 24028906 )
2013
26
Adolescent ischemic stroke associated with anabolic steroid and cannabis abuse. ( 23382306 )
2013
27
WITHDRAWN: Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. ( 23780682 )
2013
28
Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. ( 22821384 )
2013
29
Pathways to Psychosis in Cannabis Abuse. ( 23491968 )
2013
30
Psychometric Properties of the Cannabis Abuse Screening Test in Hungarian Samples of Adolescents and Young Adults. ( 24217457 )
2013
31
Monitoring of chronic Cannabis abuse: an LC-MS/MS method for hair analysis. ( 23305934 )
2013
32
Cannabis abuse is associated with better emotional memory in schizophrenia: a functional magnetic resonance imaging study. ( 23906663 )
2013
33
Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. ( 22907121 )
2013
34
Contributions of ethnicity to differential item functioning of cannabis abuse and dependence symptoms. ( 23384380 )
2013
35
A validation of the Cannabis Abuse Screening Test (CAST) using a latent class analysis of the DSM-IV among adolescents. ( 23519957 )
2013
36
Cannabis abuse in adolescence and the risk of psychosis: A brief review of the preclinical evidence. ( 23916409 )
2013
37
Validation of the Cannabis Abuse Screening Test in a sample of cannabis inpatients. ( 22472963 )
2012
38
Alcohol and cannabis abuse/dependence symptoms and life satisfaction in young adulthood. ( 21733007 )
2012
39
Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox. ( 22716154 )
2012
40
Cannabis abuse and vulnerability to psychosis: targeting preventive services. ( 22239586 )
2012
41
The validity of DSM-IV cannabis abuse and dependence criteria in adolescents and the value of additional cannabis use indicators. ( 21205060 )
2011
42
Psychometric properties of the Cannabis Abuse Screening Test (CAST) in a French sample of adolescents. ( 20869178 )
2011
43
Developmental pathways to adolescent cannabis abuse and dependence: child maltreatment, emerging personality, and internalizing versus externalizing psychopathology. ( 21534646 )
2011
44
Bilateral testicular self-castration due to cannabis abuse: a case report. ( 21861879 )
2011
45
Effects of handedness (left vs right) and cannabis abuse on intermanual coordination and negative symptoms in schizophrenic patients of the paranoid type. ( 21082479 )
2011
46
Psychometric modeling of cannabis initiation and use and the symptoms of cannabis abuse, dependence and withdrawal in a sample of male and female twins. ( 21507586 )
2011
47
Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. ( 20600341 )
2010
48
Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatients. ( 19932824 )
2010
49
Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. ( 19997844 )
2010
50
From child maltreatment to adolescent cannabis abuse and dependence: a developmental cascade model. ( 20883588 )
2010

Variations for Cannabis Abuse

Expression for Cannabis Abuse

Search GEO for disease gene expression data for Cannabis Abuse.

Pathways for Cannabis Abuse

Pathways related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 BDNF CHRNA3 CHRNB3 NGF
2
Show member pathways
12.22 BDNF CNR1 NGF
3
Show member pathways
11.41 CHRNA3 CHRNB3
4
Show member pathways
11.37 BDNF NGF
5 11.33 BDNF NGF
6
Show member pathways
11.19 BDNF NGF
7
Show member pathways
11.04 BDNF NGF
8 10.96 BDNF CNR1 NGF
9
Show member pathways
10.84 CNR1 CNR2
10 10.4 CNR1 CNR2

GO Terms for Cannabis Abuse

Cellular components related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 acetylcholine-gated channel complex GO:0005892 8.62 CHRNA3 CHRNB3

Biological processes related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cation transmembrane transport GO:0098655 9.48 CHRNA3 CHRNB3
2 excitatory postsynaptic potential GO:0060079 9.46 CHRNA3 CHRNB3
3 sensory perception of pain GO:0019233 9.43 CNR1 CNR2
4 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.4 CNR1 CNR2
5 response to nicotine GO:0035094 9.37 CHRNB3 CNR1
6 synaptic transmission, cholinergic GO:0007271 9.32 CHRNA3 CHRNB3
7 negative regulation of nitric-oxide synthase activity GO:0051001 9.26 CNR1 CNR2
8 negative regulation of mast cell activation GO:0033004 9.16 CNR1 CNR2
9 negative regulation of action potential GO:0045759 8.96 CNR1 CNR2
10 cannabinoid signaling pathway GO:0038171 8.62 CNR1 CNR2

Molecular functions related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular ligand-gated ion channel activity GO:0005230 9.32 CHRNA3 CHRNB3
2 ligand-gated ion channel activity GO:0015276 9.26 CHRNA3 CHRNB3
3 acetylcholine binding GO:0042166 9.16 CHRNA3 CHRNB3
4 acetylcholine-gated cation-selective channel activity GO:0022848 8.96 CHRNA3 CHRNB3
5 cannabinoid receptor activity GO:0004949 8.62 CNR1 CNR2

Sources for Cannabis Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....